Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash & Equivalents (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Cash & Equivalents for 4 consecutive years, with $319.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 131.21% to $319.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $319.8 million through Dec 2025, up 131.21% year-over-year, with the annual reading at $319.8 million for FY2025, 131.21% up from the prior year.
  • Cash & Equivalents hit $319.8 million in Q4 2025 for Taysha Gene Therapies, up from $297.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $319.8 million in Q4 2025 to a low of $36.9 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $146.7 million across 4 years, with a median of $131.1 million in 2024.
  • Biggest YoY gain for Cash & Equivalents was 344.68% in 2023; the steepest drop was 36.11% in 2023.
  • Year by year, Cash & Equivalents stood at $87.9 million in 2022, then surged by 62.04% to $142.4 million in 2023, then decreased by 2.88% to $138.3 million in 2024, then surged by 131.21% to $319.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for TSHA at $319.8 million in Q4 2025, $297.3 million in Q3 2025, and $312.8 million in Q2 2025.